NCT07405970RecruitingPhase 3
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
A Phase 3 Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Systemic Lupus Erythematosus.
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 316 (estimated)
- First submitted
- 5 Feb 2026
- Start date
- 10 Apr 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- Beijing Mabworks Biotech Co., Ltd.
- Diseases
- Lupus (SLE)
- NCT number
- NCT07405970
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 316
- From 10 Apr 2026 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received rituximab or any B-cell depleting drug within 9 months prior to the first dose;
- Received cyclophosphamide within 8 weeks prior to the first dose; received calcineurin inhibitors (cyclosporine, tacrolimus, etc., except for topical use) or plasma exchange therapy within 4 weeks prior to the first dose;
- Received a B-cell stimulating factor inhibitor such as Belimumab, and Telitacicept within 8 weeks prior to the first administration;
- TNF inhibitor, interleukin monoclonal antibody, JAK inhibitor, BTK inhibitor, TYK2 inhibitor, or thalidomide within 4 weeks prior to the first administration;
- Received live or attenuated vaccination within 28 days prior to the first administration;
- Participated in other clinical trials within 28 days prior to the first administration;
- Concomitant with other serious diseases;
Other illness
- Positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with HBV DNA titer above the normal range; positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV);
- Subjects with known history of severe allergic reactions to humanized monoclonal antibodies MIL62;
- Other conditions unsuitable for participation in this study determined by the Investigator.
Lab values
- Subjects with CD4+ T lymphocyte count \< 200 cells/μL;
Other
- Unsufficient organ function;
- Breastfeeding or pregnant women;
- Childbearing potential and unwillingness or impossibility to comply with a scientifically acceptable birth-control method;
Who the study is looking for
- Age 18-80 ;
- Diagnosis of systemic lupus erythematosus according to European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria ;
- Positive antinuclear antibodies (ANA) ≥ 1:80 at screening or positive anti- dsDNA ;
- High disease activity at screening ,SLEDAI-2000 score ≥8 (excluding alopecia score);
- On a stable dose of one or more standard treatments for SLE prior to the first administration；
- Able and willing to provide written informed consent and to comply with the study protocol.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.